Table 2.
Nanocarrier-based TO-formulations for cancer therapy in clinical trails.
| Delivery system | Name | TOs subtypes | Target | Disease | Clinical phase |
|---|---|---|---|---|---|
| LNP | siRNA-EphA2-DOPC [404] | siRNA | EphA2 | Advanced solid tumors | Ⅰ |
| TKM-080301 [80] | siRNA | PLK1 | Advanced hepatocellular carcinoma | Ⅰ/Ⅱ | |
| DCR-MYC [405] | siRNA | MYC | Hepatocellular carcinoma | Ib/2 | |
| ALN-VSP02 [19] | siRNA | VEGF | Solid tumors | Ⅰ | |
| lipo-MERIT [406] | mRNA | TAA | Melanoma | Ⅰ | |
| TNBC-MERIT [407] | mRNA | TAA | Triple negative breast cancer | Ⅰ | |
| mRNA-2416 [400] | mRNA | OX40L | Advanced solid tumor | Ⅰ/Ⅱ | |
| Pbi-shRNA-STMN1 [408] | shRNA | STMN1 | Advanced liver cancer, solid tumor | Ⅰ | |
| MTL-CEBPA [409] | saRNA | CEBPA | Liver cancer | Ⅰ | |
| EV | iExosomes [410] | siRNA | KRASG12D mutation | Pancreatic cancer | Ⅰ |
| AuNP | NU-0129 [411] | RNA | BCL2L12 | Glioblastoma multiforme | Ⅰ |
Abbreviations: LNP, lipid-based nanoparticles; EV, extracellular vesicle; AuNP, gold nanoparticles; EphA2, Ephrin type-A receptor 2; PLK1, serine/threonine-protein kinase PLK1; MYC, MYC Proto-Oncogene; VEGF, vascular endothelial growth factor; TAA, Tumor-associated antigen; OX40L, tumor necrosis factor ligand superfamily member 4; STMN1, human stathmin 1; CEBPA, CCAAT/enhancer binding protein alpha; KRASG12D, GTPase KRas G12D; BCL2L12, Bcl-2-like protein 12.